Q3 FY2026 · ended Sep 30, 2026 · Revenue $102.89M, +23.9% YoY · Filed Nov 5, 2026
Castle Biosciences, Inc. (CSTL) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $102.9 million and a net loss of $4.1 million. Free cash flow was $12.2 million. As of Sep 30, 2026 it held $277.7 million in cash and investments and $36.6 million in total debt.
Revenue
$102.89M
+23.9% vs year-ago quarter
Net income
$-4.10M
-718.4% vs year-ago quarter
Operating cash flow
$19.74M
-12.8% vs year-ago quarter
Free cash flow
$12.25M
+57.1% vs year-ago quarter
EPS
$-0.13
-550.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
30.82M
+5.6% vs year-ago quarter
Net cash
$241.09M
Q3 FY2026
Operating margin
-7.4%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CSTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Friendswood, TX
- SEC filer status
- Accelerated filer
- SEC CIK
- 1447362
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $102.9M | $103.5M | $83.7M | $87.0M | $83.0M |
| Operating income | -$2.7M | -$3.1M | -$18.4M | -$3.8M | -$6.8M |
| Net income | -$4.1M | -$2.1M | -$14.5M | -$2.3M | -$501,000 |
| Diluted EPS | -$0.13 | -$0.07 | -$0.49 | -$0.08 | -$0.02 |
| Operating cash flow | $19.7M | $15.2M | -$22.1M | $26.9M | $22.6M |
| Free cash flow | $12.2M | $6.6M | -$34.6M | $19.7M | $7.8M |
| Total assets | $579.4M | $561.2M | $547.8M | $578.6M | $562.8M |
| Total liabilities | $101.0M | $91.1M | $86.4M | $107.7M | $95.7M |
| Stockholders' equity | $478.4M | $470.0M | $461.4M | $470.9M | $467.0M |
| Cash and investments | $277.7M | $266.8M | $261.7M | $299.5M | $287.5M |
| Total debt | $36.6M | $36.6M | $36.7M | $37.0M | $37.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 890 Castle Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.